NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant ...